Immune combo tackles deadly brain tumor in early trial
NCT ID NCT04606316
First seen Feb 23, 2026 · Last updated Apr 29, 2026 · Updated 5 times
Summary
This early-phase study tests two immunotherapy drugs (nivolumab and ipilimumab) given before surgery in people with recurrent glioblastoma, an aggressive brain cancer. The goal is to see if the drugs are safe and how they affect immune cells in the tumor. About 63 participants will receive either the drug combination or a placebo before their surgery.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for GLIOBLASTOMA are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Dana Farber Cancer Institute
Boston, Massachusetts, 02115, United States
-
Memorial Sloan Kettering Cancer Center
New York, New York, 10065, United States
-
Stanford University
Stanford, California, 94305, United States
-
University of California Los Angeles
Los Angeles, California, 90095, United States
Conditions
Explore the condition pages connected to this study.